Table 2.
Univariable analysis of transplants outcomes according to donor type
| Outcome* | MSD | MUD | Haplo | p |
|---|---|---|---|---|
| Acute GvHD, % (95% CI) | ||||
| Grades II–IV | 17 (12–23) | 28 (22–34) | 26 (23–29) | 0.03 |
| Grades III–IV | 6 (4–10) | 8 (5–11) | 9 (7–12) | 0.2 |
| Chronic GvHD, % (95% CI) | ||||
| Overall | 34 (26–41) | 32 (25–39) | 30 (26–33) | 0.3 |
| Extensive type | 14 (9–20) | 18 (13–25) | 10 (8–13) | 0.003 |
| NRM, % (95% CI) | 10 (6–15)) | 14 (9–19) | 23 (20–26) | < 0.001 |
| RI, % (95% CI) | 33 (26–40) | 25 (19–31) | 23 (20–26) | 0.02 |
| LFS, % (95% CI) | 57 (49–65) | 62 (55–69) | 54 (51–58) | 0.2 |
| OS, % (95% CI) | 64 (56–72) | 68 (62–75) | 61 (58–65) | 0.1 |
| GRFS, % (95% CI) | 45 (37–53) | 42 (35–50) | 46 (42–50) | 0.9 |
*Acute GvHD: 100-day cumulative incidence; cGvHD, NRM, and RI: cumulative incidence at 2 years; DFS, OS, and GRFS: survival probability at 2 years
GvHD graft-versus-host disease, CI confidence interval, NRM non-relapse mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival, GRFS graft-versus-host disease and relapse-free survival